GSE252944 AKT inhibition 11 v 6 human up (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE252944_AKT inhibition_11_v_6_human_up.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE252944_AKT inhibition_11_v_6_human_up.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE252944_AKT inhibition_11_v_6_human_up.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE252944_AKT inhibition_11_v_6_human_up.

Results found

Linked to

 

Label

Description

 

Gene

MT-CO2 pseudogene 12

Gene

TPTE pseudogene 1

Gene

zinc finger protein 37B, pseudogene

Gene

ALDH1A3 antisense RNA 1

Gene

RAB4A antisense RNA 1

Gene

RNF32 divergent transcript

Gene

long intergenic non-protein coding RNA 863

Gene

Rho associated coiled-coil containing protein kinase 1 pseudogene 1

Gene

napsin B aspartic peptidase (pseudogene)

Gene

MSANTD2 antisense RNA 1

  • Gene

    MT-CO2 pseudogene 12


  • Gene

    TPTE pseudogene 1


  • Gene

    zinc finger protein 37B, pseudogene


  • Gene

    ALDH1A3 antisense RNA 1


  • Gene

    RAB4A antisense RNA 1


  • Gene

    RNF32 divergent transcript


  • Gene

    long intergenic non-protein coding RNA 863


  • Gene

    Rho associated coiled-coil containing protein kinase 1 pseudogene 1


  • Gene

    napsin B aspartic peptidase (pseudogene)


  • Gene

    MSANTD2 antisense RNA 1

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.